Kestra Medical Technologies (NASDAQ:KMTS) Announces Earnings Results

Kestra Medical Technologies (NASDAQ:KMTS) posted its quarterly earnings results on Thursday. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.06), Zacks reports.

Kestra Medical Technologies Price Performance

Shares of Kestra Medical Technologies stock traded up $0.39 during midday trading on Thursday, hitting $24.91. 329,897 shares of the company were exchanged, compared to its average volume of 284,634. The firm has a 50 day simple moving average of $25.50 and a 200-day simple moving average of $20.76. The company has a debt-to-equity ratio of 0.23, a current ratio of 6.84 and a quick ratio of 6.84. The firm has a market cap of $1.28 billion and a P/E ratio of -9.77. Kestra Medical Technologies has a 52 week low of $13.25 and a 52 week high of $30.00.

Institutional Investors Weigh In On Kestra Medical Technologies

Institutional investors and hedge funds have recently made changes to their positions in the company. Millennium Management LLC bought a new stake in shares of Kestra Medical Technologies in the 1st quarter worth about $11,036,000. Geode Capital Management LLC boosted its position in Kestra Medical Technologies by 718.5% in the second quarter. Geode Capital Management LLC now owns 325,326 shares of the company’s stock valued at $5,395,000 after buying an additional 285,579 shares in the last quarter. Alliancebernstein L.P. grew its stake in Kestra Medical Technologies by 13.7% during the third quarter. Alliancebernstein L.P. now owns 1,491,970 shares of the company’s stock worth $35,449,000 after buying an additional 179,885 shares during the last quarter. UBS Group AG increased its holdings in shares of Kestra Medical Technologies by 173.7% during the third quarter. UBS Group AG now owns 200,150 shares of the company’s stock worth $4,756,000 after buying an additional 127,026 shares in the last quarter. Finally, Longaeva Partners L.P. raised its stake in shares of Kestra Medical Technologies by 342.7% in the third quarter. Longaeva Partners L.P. now owns 136,182 shares of the company’s stock valued at $3,236,000 after acquiring an additional 105,421 shares during the last quarter.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. BTIG Research assumed coverage on shares of Kestra Medical Technologies in a research report on Tuesday, November 18th. They set a “buy” rating and a $32.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Kestra Medical Technologies in a report on Wednesday, October 8th. Finally, Wall Street Zen downgraded Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research report on Sunday, September 28th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $28.00.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.